ORAL AND MAXILLOFACIAL PATHOLOGY OOOO

e208 Abstracts February 2014

Design: Sixteen cases of SCCL were studied by immunohisto-chemistry and evaluated according to histological grading andhistological features. Results: The expression of p16INK4a was thehighest among proteins studied, with 68.7% of positive cases,especially in well-differentiated SCCL and in keratin pearls,followed by Bcl-2 expression in 42.8% of cases, especially inmoderately differentiated SCCL and in cords. Cyclin D1 wasexpressed only in 37.5% of cases, especially in well-differentiatedSCCL and in cords of neoplastic cells. Conclusion: It is suggestedthat p16INK4a may inhibit the cyclin D1 in SCCL, since itsexpression was present in most cases, contrary of that observedfor cyclin D1, in a manner different from other tumors. Bcl-2should not exert its anti-apoptotic role properly in SCCL, since itsexpression was lower than expected.

PE-392 - EXPRESSION OF BIOLOGICAL MARKERS INORAL SQUAMOUS CELL CARCINOMA. JOSÉRICARDO SOUSA COSTA, SABRINA MOURE, EMERSONFERREIRA HONÓRIO, MILENE CASTILHOS OLIVEIRA,SIMONE MÁRCIA DOS SANTOS MACHADO, HUMBERTOTHOMAZI GASSEN, SÉRGIO AUGUSTO MIGUENS JR.PROGRAMA DE PG EM ODONTOLOGIAeULBRA,CAMPUS CANOAS.

The use of toluidine blue (TB) as an ancillary method seemsto be helpful to determine the site with the most severe degree ofalterations based on staining intensity. Immunohistochemistrycontributes to the diagnosis and treatment of squamous cell car-cinoma (SCC). This study evaluated the expression of cell pro-liferation markers in patients with a suspected diagnosis of oralSCC, with biopsy fragments coming from areas with the mostintense TB stains. Those areas were removed and analyzedmicroscopically (hematoxylin-eosin [HE] stain; immunohisto-chemistry with anti-CD31, anti-CD34, factor VIII, Ki-67, andp53). The control group consisted of fragments less stained byTB. A positive immune marking was found, suggesting the tu-mors had a high proliferative activity. The use of immune markersadds to the behavioral and prognostic understanding of SCC. TBseems to be helpful in choosing fragments with more proliferativeactivity.

PE-393 - EXPRESSION OF PLUNC (BPIF) FAMILYMEMBERS IN MINOR SALIVARY GLAND OF PATIENTSWITH ORAL GRAFT-VERSUS-HOST DISEASE. ANDRÉIAAPARECIDA DA SILVA, TÂNIA CRISTINA BENETTISOARES, FELIPE PAIVA FONSECA, MARIA ELVIRAPIZZIGATTI CORREA, MARIA LETÍCIA CINTRA, LYNNEBINGLE, PABLO AGUSTIN VARGAS. SCHOOL OFDENTISTRY OF PIRACICABA, CAMPINAS, UNIVERSITYFOP/UNICAMP.

This study analyzed the expression of PLUNC (BPIF) pro-teins, putative host-defense proteins, in the minor salivary glandof patients diagnosed with oral graft-versus-host disease(GVHD). Material and Methods: We analyzed the expression ofPLUNCs (BPIF) protein using immunohistochemistry from bi-opsy samples of the minor salivary gland of patients (n ¼ 10)diagnosed with oral GVHD. Clinical data were collected frommedical records. Results: SPLUNC 1 expression was detected inthe mucous acini, and SPLUNC 2A were seen in the serous cells.There was a higher expression of SPLUNC 1 antibody in thesecases, but no statistical significance was observed. Conclusion:PLUNC (BPIF) proteins are differentially expressed in the minorsalivary gland of patients with oral GVHD. Further studies are

needed to better understand the biological processes involvedin PLUNC expression and the significance of the differentialexpression patterns.

PE-394 - EXPRESSION OF SPLUNC2A IN PATIENTSWHO UNDERWENT HEAD AND NECK RADIO-THERAPY. WILFREDO ALEJANDRO GONZÁLEZ-ARRIAGADA, LARA MARIA ALENCAR RAMOS, ANDREIAAPARECIDA DA SILVA, JOSÉ RIBAMAR SABINO-BEZERRA JUNIOR, PABLO AGUSTIN VARGAS, LYNNEBINGLE, MÁRCIO AJUDARTE LOPES. FOP-UNICAMP.

This study analyzed SPLUNC2A expression in patients whounderwent head and neck radiotherapy and its associated side-effects. Study Design: Unstimulated whole-mouth saliva of headand neck cancer patients was collected before, during, and afterradiotherapy. SPLUNC2A expression was analyzed by Westernblotting. Results: Thirty-two patients were included (mean age58.3 years). Nineteen patients were irradiated in the oral cavityand 13 patients in the neck. Analysis included total SPLUNC2A,glycosylated, and non-glycosylated bands expression. Increasingnon-glycosylated SPLUNC2A expression after radiotherapywas associated with severe mucositis; reducing expression wasassociated with candidiasis. Women, older patients, adjuvantchemotherapy, higher irradiation dose, and radiation field wereassociated with decreasing expression of PLUNC during and aftertherapy. Conclusion: The present study reports the association ofSPLUNC2A expression in saliva with side effects of radio-therapy, suggesting that PLUNC proteins may play an importantrole in the oral microenvironment.

PE-395 - FLUORESCENCE SPECTROSCOPY FOR EVAL-UATION OF SAFETY MARGINS IN INDIVIDUALSWITH SURGICALLY TREATED SQUAMOUS CELL CAR-CINOMAOF THE ORAL CAVITY. ANA LUCIA NORONHAFRANCISCO, WAGNER RAFAEL CORRER, THIAGOCELESTINO CHULAM, JOÃO GONÇALVES FILHO,NATALIE KELNER, CRISTINA KURACHI, LUIZ PAULOKOWALSKI. DEPARTMENT OF ORAL DIAGNOSIS,SCHOOL OF DENTISTRY OF PIRACICABA, UNIVERSITYOF CAMPINAS (UNICAMP).

Oral cancer is a public health problem. It is usually detectedin advanced stages, which decreases survival rates. Fluorescencespectroscopy (FS) is a noninvasive diagnostic tool that can aidin cancer detection, is simple, and is accurate. FS evaluates thebiochemical composition and structure of the tissue fluorescencespectrum. This study discriminated healthy tissue from tumorand margins using FS. The sample consisted of 56 individualswho underwent FS; 28 patients had cancer and 28 were healthyvolunteers. Male patients accounted for 60.7% of the sample;the mean age was 58.46 years. The spectra were classifiedand compared to histopathology to determine the usefulness ofFS in diagnostic discrimination. Variation was seen betweenanatomical sites and the safety margins of the tumor. Inconclusion, FS can potentially be used as an aid in the diagnosisof oral cancer.

PE-396 - FREQUENCY OF ORAL MANIFESTATIONS OFCHRONIC GRAFT-VERSUS-HOST DISEASE IN HE-MATOPOIETIC STEM CELL TRANSPLANT RECIPI-ENTS. CESAR WERNECK NOCE, ALESSANDRA GOMES,MARIA CLÁUDIA R. MOREIRA, VANESSA SHCAIRA,MARIA ELVIRA P. CORRÊA, ÂNGELO MAIOLINO,